WallStreetZenWallStreetZen

NYSE: EBS
Emergent Biosolutions Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Emergent Biosolutions revenue was $1.04B for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $194.7M, down 33.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EBS annual revenue was $1.0B, with -0.5% growth year-over-year.

EBS past revenue growth

How has EBS's revenue growth performed historically?

Company
-0.54%
Industry
10.38%
Market
20.68%
EBS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EBS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EBS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EBS revenue history

Current Revenue
$1.0B
Current Earnings
-$190.6M
Current Profit Margin
-18.3%

Be the first to know when EBS announces revenue.

EBS Revenue History By Year

EBS Yearly RevenueEBS RevenueEBS ChangeEBS Revenue Growth
2024-12-31$1.04B-$5.70M-0.54%
2023-12-31$1.05B-$68.20M-6.10%
2022-12-31$1.12B-$656.10M-36.99%
2021-12-31$1.77B$196.30M+12.45%
2020-12-31$1.58B$471.30M+42.61%
2019-12-31$1.11B$323.60M+41.36%
2018-12-31$782.40M$221.50M+39.49%
2017-12-31$560.90M$72.10M+14.75%
2016-12-31$488.80M-$531.00k-0.11%
2015-12-31$489.33M$84.87M+20.98%
2014-12-31$404.47M$91.72M+29.33%
2013-12-31$312.75M$30.86M+10.95%
2012-12-31$281.89M$8.50M+3.11%
2011-12-31$273.38M-$12.79M-4.47%
2010-12-31$286.17M$51.39M+21.89%
2009-12-31$234.79M$56.23M+31.49%
2008-12-31$178.55M-$4.36M-2.38%
2007-12-31$182.92M$30.18M+19.76%
2006-12-31$152.73M$22.04M+16.87%
2005-12-31$130.69M$47.19M+56.52%
2004-12-31$83.49M$27.73M+49.71%
2003-12-31$55.77MN/AN/A

1 of 2

Emergent Biosolutions Revenue FAQ

What was EBS's revenue last quarter?

On Invalid Date, Emergent Biosolutions (NYSE: EBS) reported Q4 2024 revenue of $194.70 million up 29.61% year over year. In the same quarter last year, Emergent Biosolutions's revenue was $276.60 million.

What was Emergent Biosolutions's revenue in 2024?

Emergent Biosolutions's annual revenue for the twelve months ending Dec 31, 2024 was $1.04 billion, a 0.54% decrease year over year.

How much does Emergent Biosolutions make in a day?

Based on Emergent Biosolutions annual revenue for the past five years, EBS makes an average of $3,595,232.88 per day.

What was Emergent Biosolutions's annual revenue growth in the past year?

As of Q2 2025, Emergent Biosolutions's revenue has grown -0.54% year over year. This is 10.92 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.38%. Emergent Biosolutions's revenue in the past year totaled $1.04 billion.

How much does Emergent Biosolutions make in a year?

Emergent Biosolutions's revenue by year for the past five years is:
  • Emergent Biosolutions's revenue for the twelve months ending Dec 31, 2024 was $1.04 billion, a 0.54% decrease year over year.
  • Emergent Biosolutions's annual revenue for Dec 31, 2023 was $1.05 billion, a 6.1% decrease from 2022.
  • Emergent Biosolutions's annual revenue for 2022 was $1.12 billion, a 36.99% decrease from 2021.
  • Emergent Biosolutions's annual revenue for 2021 was $1.77 billion, a 12.45% increase from 2020.
  • Emergent Biosolutions's annual revenue for 2020 was $1.58 billion, a 42.61% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.